Clinical Trial

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Protocol Amendment History 1 change
minor Trial arms changed: 5 -> 9 2026-08-04
Trial Details
NCT Number NCT06885034
Lead Sponsor GlaxoSmithKline
Conditions Gastrointestinal Neoplasms
Enrollment 451 participants
Start Date 2025-06-11
Primary Completion 2028-01-10 (estimated)
Study Completion 2029-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-03